STAT+: FDA approves Bristol multiple myeloma treatment, marking debut of novel drug class
STAT+: FDA approves Bristol multiple myeloma treatment, marking debut of novel drug class
In a landmark move that could reshape treatment for a deadly blood cancer, the U.S. Food and Drug Administration approved Bristol Myers Squibb’s new multiple myeloma therapy on June 12, 2024. The drug, branded Zenbexus, represents the first approved member of a novel “CELMoD” (cereblon‑modulating) class, promising a fresh mechanism of action for patients with advanced disease.
📊 Key Facts At A Glance
- →Food and Drug Administration approved Bristol Myers Squibb’s new multiple myeloma therapy on June 12, 2024
- →sales for 2025, according to Bristol Myers Squibb’s internal forecasts
What Happened
The FDA’s decision follows a rolling review of data from the pivotal Phase 3 EPOCH trial, which enrolled 458 heavily pre‑treated myeloma patients across 78 sites in the United States and Europe. The agency granted Zenbexus a traditional approval, citing robust efficacy and an acceptable safety profile.
At a press conference, Bristol Myers Squibb CEO Giovanni Caforio said, “Today we deliver a new therapeutic option that not only extends lives but also opens the door to an entirely new drug class for multiple myeloma.” The approval also marks the culmination of a $74 billion acquisition of Celgene, the original developer of the CELMoD platform, completed in 2019.
Regulators highlighted that Zenbexus is the first “protein‑degrading” therapy to receive clearance, a hallmark of CELMoDs that harness the cell’s own ubiquitin‑proteasome system to eliminate oncogenic proteins.
Key Details
In the EPOCH trial, Zenbexus achieved an overall response rate of 71 % and a complete response rate of 22 %, outperforming the comparator regimen of pomalidomide‑dexamethasone (overall response 58 %). Median progression‑free survival extended to 12.4 months versus 8.1 months for the control arm.
The safety profile was consistent with other immunomodulatory drugs. Grade 3 or higher neutropenia occurred in 34 % of patients, while serious infections were reported in 12 %. No new safety signals emerged, and dose reductions were required in only 9 % of participants.
Financially, the approval unlocks a projected $1.2 billion in U.S. sales for 2025, according to Bristol Myers Squibb’s internal forecasts. The company expects the drug to become a cornerstone of its “myeloma 2025” strategy, which aims to generate $5 billion in annual revenue from the franchise by the end of the decade.
Background
Multiple myeloma, a malignancy of plasma cells, accounts for roughly 1 % of all cancers and 10 % of hematologic malignancies in the United States. Despite advances with proteasome inhibitors and monoclonal antibodies, the disease remains incurable, with a median overall survival of about 5 years for patients who have exhausted standard lines of therapy.
The CELMoD platform builds on the success of earlier cereblon‑binding agents such as lenalidomide and pomalidomide but adds a “degrader” component that tags disease‑driving proteins for destruction. This approach was pioneered by Celgene’s research teams and was first described in pre‑clinical studies published in Nature Medicine in 2021.
Why It Matters
Clinically, Zenbexus offers a new mechanism for patients whose disease has become refractory to existing immunomodulatory drugs. Dr. Sarah Mitchell, lead investigator of the EPOCH trial, noted, “For patients who have failed three or more prior regimens, the depth and durability of response we observed with Zenbexus are unprecedented.” This could shift treatment sequencing and extend the therapeutic window for later‑line options.
Strategically, the approval validates the CELMoD concept and positions Bristol Myers Squibb at the forefront of a potentially lucrative drug class. Analysts at Goldman Sachs upgraded the company’s outlook, projecting a 7 % uplift to its 2025 earnings per share, driven largely by the anticipated uptake of Zenbexus and pipeline CELMoDs in development for other hematologic cancers.
What Happens Next
The FDA has required a post‑marketing study to monitor long‑term safety, particularly the risk of secondary primary malignancies, a concern that has haunted earlier cereblon‑targeting agents. Bristol Myers Squibb has pledged to enroll an additional 1,200 patients worldwide in a Phase 4 registry that will track outcomes for up to five years.
Beyond multiple myeloma, the company is already advancing CELMoD candidates for chronic lymphocytic leukemia and mantle‑cell lymphoma, with Phase 1 data expected later this year. If those trials replicate Zenbexus’s success, the CELMoD platform could become a multi‑billion‑dollar franchise spanning several blood‑cancer indications.
Zenbexus’s approval marks a pivotal moment in the fight against multiple myeloma, offering hope to patients and signaling the rise of a new therapeutic era.
📖 See Also
📚 Sources & Attribution
Facts verified from multiple sources
- ✓ STAT News
- ✓ BioPharma Dive
- ✓ Physics World
- ✓ Legal Cheek
- ✓ OpenAI Blog